Document is current
Any future updates will be listed below
-
Authors
Raguram, Aditya https://orcid.org/0000-0002-5749-7308
An, Meirui https://orcid.org/0000-0002-4006-8670
Chen, Paul Z. https://orcid.org/0000-0001-5261-1610
Liu, David R. https://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UG3AI150551, U01AI142756)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL136135)
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY009339)
Bill and Melinda Gates Foundation (Liu grant)
Howard Hughes Medical Institute (Liu investigatorship)
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 10 October 2024
First Online: 13 November 2024
Competing interests
: A.R. and D.R.L. have filed patent applications on this work through the Broad Institute. D.R.L. is a consultant and/or equity owner for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics, companies that use or deliver genome editing or epigenome engineering agents. The remaining authors declare no competing interests.
